Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress Inhibrx Biosciences is preparing to present groundbreaking findings on a novel drug combination for Ewing Sarcoma at the ESMO conference in March 2026.

Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress #USA #San_Diego #Inhibrx #ESMO_Congress #Ewing_Sarcoma

Hengrui Pharma Shines at ESMO 2025 with Its Groundbreaking Oncology Innovations At the ESMO 2025 Congress, Hengrui Pharma unveiled 46 innovative studies, solidifying its role in global oncology research and patient care.

Hengrui Pharma Shines at ESMO 2025 with Its Groundbreaking Oncology Innovations #Germany #Berlin #Hengrui_Pharma #oncology_research #ESMO_Congress

Significant Advancements in Lung Cancer Treatment with Sacituzumab Tirumotecan from Recent Clinical Trials Recent results from the Phase 3 OptiTROP-Lung04 trial for sacituzumab tirumotecan show promising benefits for lung cancer patients, marking a pivotal moment in treatment options.

Significant Advancements in Lung Cancer Treatment with Sacituzumab Tirumotecan from Recent Clinical Trials #China #Chengdu #Lung_Cancer #sacituzumab_tirumotecan #ESMO_Congress

Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress Caris Life Sciences is set to present six groundbreaking studies at the ESMO 2025 Congress, showcasing advancements in precision medicine and multiomics.

Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress #United_States #Caris_Life_Sciences #Irving #Precision_Medicine #ESMO_Congress

Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 Lupin Limited is set to present critical Phase 1 data on LNP3693, a STING agonist, at the ESMO Congress 2025, highlighting potential advances in cancer treatment.

Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin Lupin Limited is set to present data from its Phase 1 trial of LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, showcasing its potential in treating advanced solid tumors.

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 Lupin Limited announces the presentation of Phase-1 findings for LNP3693 at the ESMO Congress 2025, highlighting its potential in cancer treatment.

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Leap Therapeutics to Showcase Final Clinical Findings of DeFianCe Study at ESMO Congress 2025 Leap Therapeutics, Inc. is set to present the final clinical outcomes from the DeFianCe study, featuring their innovative anti-DKK1 antibody, at ESMO 2025.

Leap Therapeutics to Showcase Final Clinical Findings of DeFianCe Study at ESMO Congress 2025 #USA #Cambridge #Leap_Therapeutics #ESMO_Congress #DKK1_antibody

Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025 Lutris Pharma is set to present data from its Phase 2 trial of LUT014 gel, aimed at treating acneiform rash induced by EGFR inhibitors, at ESMO 2025.

Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025 #Israel #Tel_Aviv #Lutris_Pharma #LUT014 #ESMO_Congress